#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cardiac failure acute Cholangitis sclerosing Sarcoma Lymphoma Atypical haemolytic uraemic syndrome Cryoglobulinaemia Anti-HLA antibody test positive Cutaneous T-cell lymphoma refractory Neurofibromatosis Chronic myeloid leukaemia (in remission) Malignant glioma Bronchopulmonary aspergillosis Hepatic angiosarcoma Short-bowel syndrome Univentricular heart More trials…

    Learn about Rare Diseases

    Lysosomal storage disorder – Basic Information Indolent systemic mastocytosis – Trials in Disease Leiomyosarcoma metastatic Arterial tortuosity syndrome – Diagnostics Phenylketonuria – Treatment Familial amyotrophic lateral sclerosis – Treatment Breast angiosarcoma metastatic – Basic Information Cystic fibrosis – Basic Information Lysosomal storage disorder – Treatment Aicardi-Goutieres syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Samuraciclib ALN-961583 Bi 764524 Imetelstat Sodium Dexamethasone Acetate Tianeptine Sodium Indometacin Ph. Eur. Lucerastat RO7837195 Acetic Acid, Glacial Benztropine Mesylate Dextromethadone Hydrochloride Bay 2927088 IADADEMSTAT Ublituximab POLYSORBATE 80 Salmeterol Xinafoate Azd7798 LIPASE Clioquinol More therapies…

    Learn about Your Condition

    Rectal cancer stage II Angiopathy Diabetes insipidus Supranuclear palsy Cervix carcinoma stage II Immune thrombocytopenia Myotonic dystrophy Prinzmetal angina Procedural headache Post procedural oedema Left ventricular dysfunction Rasmussen encephalitis Metachromatic leukodystrophy Myocarditis post infection Triple negative breast cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Gastroenteropancreatic neuroendocrine tumour disease

  • Study of Gallium (68Ga) edotreotide, Fluorocholine (18F) and Fludeoxyglucose (18F) PET imaging for detection and staging of liver cancer and gastro-entero-pancreatic tumors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Fludeoxyglucose (18F)
    France

  • Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Arginine Hydrochloride
    • Dimeticone
    • Lysine Hydrochloride
    France Germany Hungary Italy The Netherlands Poland +1

  • Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour of the lung
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Dacarbazine
    • Topotecan
    • Atezolizumab
    France

  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    • Neuroendocrine tumour
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Copper (64Cu) Chloride
    • Dotatate
    • Fludeoxyglucose (18F)
    Denmark

  • Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    • Neuroendocrine tumour
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Pyruvic Acid
    • Fludeoxyglucose (18F)
    Denmark

  • Study on the Safety and Effectiveness of Cabozantinib and Lanreotide for Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Lanreotide
    • Cabozantinib
    Italy
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!